Illumina Inc. (NASDAQ:ILMN) shares were up 3.5% during trading on Thursday . The company traded as high as $182.67 and last traded at $175.00, with a volume of 5,069,324 shares trading hands. The stock had previously closed at $169.15.

A number of research analysts have commented on ILMN shares. Citigroup Inc. reiterated a “buy” rating and issued a $210.00 price objective on shares of Illumina in a research report on Friday, April 22nd. CL King started coverage on Illumina in a research report on Tuesday, June 21st. They issued a “buy” rating and a $165.00 price objective on the stock. Morgan Stanley lowered Illumina from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $130.00 to $110.00 in a research report on Tuesday, July 5th. Vetr lowered Illumina from a “buy” rating to a “sell” rating and set a $142.96 price objective on the stock. in a research report on Tuesday, July 26th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $165.00 price objective on shares of Illumina in a research report on Thursday, June 2nd. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $165.49.

The company has a 50-day moving average price of $157.28 and a 200-day moving average price of $150.39. The firm has a market capitalization of $25.17 billion and a price-to-earnings ratio of 58.79.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. During the same period last year, the company posted $0.80 EPS. The firm had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. The business’s revenue was up 11.3% compared to the same quarter last year. On average, equities analysts forecast that Illumina Inc. will post $3.53 EPS for the current fiscal year.

In other news, Director A Blaine Bowman sold 5,000 shares of the stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $135.08, for a total transaction of $675,400.00. Following the transaction, the director now owns 20,704 shares of the company’s stock, valued at approximately $2,796,696.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 10,000 shares of the stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $170.00, for a total transaction of $1,700,000.00. Following the transaction, the director now directly owns 498,061 shares in the company, valued at approximately $84,670,370. The disclosure for this sale can be found here.

Several institutional investors recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. boosted its position in Illumina by 103.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 382,838 shares of the life sciences company’s stock worth $73,484,000 after buying an additional 194,250 shares during the period. State of Tennessee Treasury Department bought a new position in Illumina during the fourth quarter worth about $18,274,000. Stephens Investment Management Group LLC boosted its position in Illumina by 2.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 129,835 shares of the life sciences company’s stock worth $24,921,000 after buying an additional 3,000 shares during the period. Calvert Investment Management Inc. boosted its position in Illumina by 21.2% in the fourth quarter. Calvert Investment Management Inc. now owns 7,137 shares of the life sciences company’s stock worth $1,370,000 after buying an additional 1,247 shares during the period. Finally, I.G. Investment Management LTD. boosted its position in Illumina by 0.8% in the fourth quarter. I.G. Investment Management LTD. now owns 49,382 shares of the life sciences company’s stock worth $9,479,000 after buying an additional 414 shares during the period.

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.